[Current dietetic and pharmacological treatment of hyperlipoproteinemia].
Secondary hyperlipoproteinaemia necessitates direct management of the main disease (hypothyroidism, nephrosis, etc.), whereas primary forms are essentially handled by dietary regimens adapted to subject types, as classified by Fredrickson-Levy-Lees and adopted by the WHO. These regimens are described and discussed schematically. Drugs may be employed if diet proves ineffectual. Anionic exchange resins, d-thyroxine, clofibrate and nicotinic acid have been shown effective for this purpose. Their mechanisms, doses and side-effects are described. The criteria governing their selection are explained in the light of the recent literature and with reference to the six phenotypes proposed by Fredrickson-Levy-Lees.
D000837:Anion Exchange Resins / Q000627:therapeutic use; D002994:Clofibrate / Q000627:therapeutic use; D003918:Dextrothyroxine / Q000627:therapeutic use; D004041:Dietary Fats; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009539:Nicotinic Acids / Q000627:therapeutic use
D000837:Anion Exchange Resins; D004041:Dietary Fats; D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D003918:Dextrothyroxine; D002994:Clofibrate
Trattamento attuale dietetico e farmacologico nelle iperlipoproteinemie